Alzheimers disease
Conditions
Interventions
Cognitive function test
EEG test
Amyloid PET scan
D009483 D004569 D000072078
Sponsors
Takanami Kentaro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Those who are between 45 and 80 years old at the time of obtaining consent. (2) Those who have received sufficient explanation and understanding of this research, and who have given their free and voluntary consent in writing. (1) Patients who are between 45 and 80 years of age at the time of consent. (2) Patients who have been diagnosed with probable Alzheimer's disease (AD) according to the NIA-AA diagnostic criteria1). (3) Those who have received sufficient explanation and understanding of this research and who have given their free and voluntary consent in writing. (4) A person who has been fully informed about this research and understands it, and who has given written consent of his/her own free will. Or, if the person lacks sufficient capacity to give consent, a person who has given written consent from a substitute.
Exclusion criteria
Exclusion criteria: Healthy subjects Those with a history of or complications from neurological diseases Those who have performed MMSE or MoCAJ within 6 months Those with mental illness Those who are taking medication that may affect EEG measurement Those with severe complications (malignant tumor, myocardial infarction, heart failure, etc.) that may affect the amyloid beta PET CT test and EEG measurement Those whose physician judges that it is difficult to perform amyloid beta PET CT test due to some physical conditions (e.g., allergy to flutemetamol (18F)) Those who, for some reason (frontal trauma, frontal skin disease, skull defect, blindness, etc.), are considered to have difficulty in performing EEG measurement and tasks during EEG measurement Pregnant women, nursing mothers, and those who wish to become pregnant during the research period Those who are participating in other research. Other persons whom the researcher, etc. judges to be undesirable as subjects of this research. Patients with Alzheimer's disease Patients with a history of or complications from neurological diseases other than Alzheimer's disease Patients with mental illness Patients who are taking medication that may affect EEG measurement Patients with severe complications (malignant tumor, myocardial infarction, heart failure, etc.) that may affect amyloid beta PETCT test and EEG measurement Patients whose physician judges that it is difficult to perform amyloid beta PET CT test due to some physical conditions (e.g., allergy to flutemetamol (18F)) Patients who, for some reason (frontal trauma, frontal skin disease, skull defect, blindness, etc.), are considered to have difficulty in performing EEG measurement and tasks during EEG measurement Pregnant women, nursing mothers, and those who wish to become pregnant during the research period Those who are participating in other research. Other persons whom the researcher, etc. judges to be undesirable as subjects of this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between qualitative assessment of amyloid beta and features obtained from EEG (EEG features) | — |
Secondary
| Measure | Time frame |
|---|---|
| The relationship between the MMSE and EEG features (EEG features) Relationship between MoCAJ and features obtained from EEG (EEG features) Summary statistics for MMSE and MoCAJ Amyloid beta Quantitative Assessment Relationship between quantitative assessment of amyloid beta and features obtained from EEG (EEG features) | — |
Contacts
Public ContactKentaro Takanami
Tohoku University Hospital
Outcome results
None listed